Study of Hairy Cell and Other Leukemias to Collect Samples for Research and Develop Immunotoxin Treatments

What this Trial Is About

Researchers are studying hairy cell leukemia HCL and other blood and lymphatic system cancers to better understand these diseases and develop new treatments, particularly recombinant immunotoxins. These immunotoxins are investigational agents that target cancer cells with antibodies carrying toxins. The study also compares HCL variants and other hematologic malignancies, aiming to identify more effective treatments through molecular and clinical analysis. Participants with hematologic malignancies or solid tumors, as well as healthy volunteers, provide various clinical samples such as blood, urine, lymph, bone marrow, and tumor tissues. While no treatment is given as part of this study, samples may be collected before or after treatment and during disease assessments. Samples can be obtained at the NIH or local providers and sent to NIH for research purposes. Participants contribute by providing samples and clinical data, which are used to study disease processes and evaluate the potential for new therapies. Follow-up occurs systematically, especially for those with HCL who have completed prior treatment, with tissue acquisition measured over 4 weeks and ongoing follow-up about every two years. The study involves adults aged 18 and older, including both cancer patients and healthy donors, with voluntary participation and no treatment administration within the protocol.

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment